Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer Downgrades Fate Therapeutics to Perform

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

byBenzinga Newsdesk

December 22, 2022

1 minute read

Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.

Citigroup Maintains Buy on Merus, Lowers Price Target to $30

By Benzinga Newsdesk

November 16, 9:01 AM

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:MRUS) with a Buy and lowers the price target from $34 to $30.

MRUS

Walmart-Vizio Deal: A Potential Boon Or Bane For Roku? Analysts Sound Off Before Q4 Earnings

By Chris Katje

February 14, 1:09 PM

A buyout of smart TV maker and connected TV advertising company Vizio could be a win for Walmart and a potential negative for Roku. What analysts are saying.

ROKU

Stifel Maintains Buy on Philip Morris Intl, Lowers Price Target to $105

By Benzinga Newsdesk

October 14, 9:32 AM

Stifel analyst Christopher Growe maintains Philip Morris Intl (NYSE:PM) with a Buy and lowers the price target from $115 to $105.

Nearly 80% Of Shiba Inu Holders Have Raked Up Losses Touching Six Figures — Over A Third Purchased Within This Range

By Mehab Qureshi

May 29, 5:20 AM

A report has revealed that a staggering 79.86% of addresses associated with the Shiba Inu (CRYPTO: SHIB) token have incurred losses reaching six figures.

$SHIB

Oppenheimer Downgrades Fate Therapeutics to Perform

Related Posts

Citigroup Maintains Buy on Merus, Lowers Price Target to $30

Walmart-Vizio Deal: A Potential Boon Or Bane For Roku? Analysts Sound Off Before Q4 Earnings

Stifel Maintains Buy on Philip Morris Intl, Lowers Price Target to $105

Nearly 80% Of Shiba Inu Holders Have Raked Up Losses Touching Six Figures — Over A Third Purchased Within This Range